Chad A Newton1, David Zhang1,2, Justin M Oldham3, Julia Kozlitina2, Shwu-Fan Ma4, Fernando J Martinez5, Ganesh Raghu6, Imre Noth4, Christine Kim Garcia1,2. 1. 1Department of Medicine and. 2. 2Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, Texas. 3. 3Department of Medicine, University of California at Davis, Davis, California. 4. 4Department of Medicine, University of Virginia, Charlottesville, Virginia. 5. 5Department of Medicine, Weill Cornell Medical Center, New York, New York; and. 6. 6Department of Medicine, University of Washington Medical Center, Seattle, Washington.
Abstract
Rationale: Immunosuppression was associated with adverse events for patients with idiopathic pulmonary fibrosis (IPF) in the PANTHER-IPF (Evaluating the Effectiveness of Prednisone, Azathioprine and N-Acetylcysteine in Patients with IPF) clinical trial. The reason why some patients with IPF experience harm is unknown. Objectives: To determine whether age-adjusted leukocyte telomere length (LTL) was associated with the harmful effect of immunosuppression in patients with IPF. Methods:LTL was measured from available DNA samples from PANTHER-IPF (interim analysis, n = 79; final analysis, n = 118). Replication cohorts included ACE-IPF (Anticoagulant Effectiveness in Idiopathic Pulmonary Fibrosis) (n = 101) and an independent observational cohort (University of Texas Southwestern Medical Center-IPF, n = 170). LTL-stratified and medication-stratified survival analyses were performed using multivariable Cox regression models for composite endpoint-free survival.Measurements and Main Results: Of the subjects enrolled in the PANTHER-IPF and ACE-IPF, 62% (49/79) and 56% (28/50) had an LTL less than the 10th percentile of normal, respectively. In PANTHER-IPF, exposure to prednisone/azathioprine/N-acetylcysteine was associated with a higher composite endpoint of death, lung transplantation, hospitalization, or FVC decline for those with an LTL less than the 10th percentile (hazard ratio, 2.84; 95% confidence interval, 1.02-7.87; P = 0.045). This finding was replicated in the placebo arm of ACE-IPF for those exposed to immunosuppression (hazard ratio, 7.18; 95% confidence interval, 1.52-33.84; P = 0.013). A propensity-matched University of Texas Southwestern Medical Center IPF cohort showed a similar association between immunosuppression and composite endpoints (death, lung transplantation, or FVC decline) for those with an LTL less than the 10th percentile (hazard ratio, 3.79; 95% confidence interval, 1.73-8.30; P = 0.00085). An interaction was found between immunosuppression and LTL for the combined PANTHER-IPF and ACE-IPF clinical trials (Pinteraction = 0.048), and the University of Texas Southwestern Medical Center IPF cohort (Pinteraction = 0.00049).Conclusions: LTL is a biomarker that may identify patients with IPF at risk for poor outcomes when exposed to immunosuppression.
RCT Entities:
Rationale: Immunosuppression was associated with adverse events for patients with idiopathic pulmonary fibrosis (IPF) in the PANTHER-IPF (Evaluating the Effectiveness of Prednisone, Azathioprine and N-Acetylcysteine in Patients with IPF) clinical trial. The reason why some patients with IPF experience harm is unknown. Objectives: To determine whether age-adjusted leukocyte telomere length (LTL) was associated with the harmful effect of immunosuppression in patients with IPF. Methods: LTL was measured from available DNA samples from PANTHER-IPF (interim analysis, n = 79; final analysis, n = 118). Replication cohorts included ACE-IPF (Anticoagulant Effectiveness in Idiopathic Pulmonary Fibrosis) (n = 101) and an independent observational cohort (University of Texas Southwestern Medical Center-IPF, n = 170). LTL-stratified and medication-stratified survival analyses were performed using multivariable Cox regression models for composite endpoint-free survival.Measurements and Main Results: Of the subjects enrolled in the PANTHER-IPF and ACE-IPF, 62% (49/79) and 56% (28/50) had an LTL less than the 10th percentile of normal, respectively. In PANTHER-IPF, exposure to prednisone/azathioprine/N-acetylcysteine was associated with a higher composite endpoint of death, lung transplantation, hospitalization, or FVC decline for those with an LTL less than the 10th percentile (hazard ratio, 2.84; 95% confidence interval, 1.02-7.87; P = 0.045). This finding was replicated in the placebo arm of ACE-IPF for those exposed to immunosuppression (hazard ratio, 7.18; 95% confidence interval, 1.52-33.84; P = 0.013). A propensity-matched University of Texas Southwestern Medical Center IPF cohort showed a similar association between immunosuppression and composite endpoints (death, lung transplantation, or FVC decline) for those with an LTL less than the 10th percentile (hazard ratio, 3.79; 95% confidence interval, 1.73-8.30; P = 0.00085). An interaction was found between immunosuppression and LTL for the combined PANTHER-IPF and ACE-IPF clinical trials (Pinteraction = 0.048), and the University of Texas Southwestern Medical Center IPF cohort (Pinteraction = 0.00049).Conclusions: LTL is a biomarker that may identify patients with IPF at risk for poor outcomes when exposed to immunosuppression.
Authors: Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann Journal: Am J Respir Crit Care Med Date: 2011-03-15 Impact factor: 21.405
Authors: Michael T Durheim; Harold R Collard; Rhonda S Roberts; Kevin K Brown; Kevin R Flaherty; Talmadge E King; Scott M Palmer; Ganesh Raghu; Laurie D Snyder; Kevin J Anstrom; Fernando J Martinez Journal: Lancet Respir Med Date: 2015-04-15 Impact factor: 30.700
Authors: Bridget D Stuart; Joyce S Lee; Julia Kozlitina; Imre Noth; Megan S Devine; Craig S Glazer; Fernando Torres; Vaidehi Kaza; Carlos E Girod; Kirk D Jones; Brett M Elicker; Shwu-Fan Ma; Rekha Vij; Harold R Collard; Paul J Wolters; Christine Kim Garcia Journal: Lancet Respir Med Date: 2014-06-16 Impact factor: 30.700
Authors: Imre Noth; Kevin J Anstrom; Sara Bristol Calvert; Joao de Andrade; Kevin R Flaherty; Craig Glazer; Robert J Kaner; Mitchell A Olman Journal: Am J Respir Crit Care Med Date: 2012-05-03 Impact factor: 21.405
Authors: Bridget D Stuart; Jungmin Choi; Samir Zaidi; Chao Xing; Brody Holohan; Rui Chen; Mihwa Choi; Pooja Dharwadkar; Fernando Torres; Carlos E Girod; Jonathan Weissler; John Fitzgerald; Corey Kershaw; Julia Klesney-Tait; Yolanda Mageto; Jerry W Shay; Weizhen Ji; Kaya Bilguvar; Shrikant Mane; Richard P Lifton; Christine Kim Garcia Journal: Nat Genet Date: 2015-04-13 Impact factor: 41.307
Authors: Cody A Schott; Christian Ascoli; Yue Huang; David L Perkins; Patricia W Finn Journal: Am J Respir Crit Care Med Date: 2020-03-01 Impact factor: 21.405
Authors: Sydney B Montesi; Jolene H Fisher; Fernando J Martinez; Moisés Selman; Annie Pardo; Kerri A Johannson Journal: Am J Respir Crit Care Med Date: 2020-08-15 Impact factor: 21.405
Authors: Simone Feurstein; Ayodeji Adegunsoye; Danijela Mojsilovic; Rekha Vij; Allison H West DePersia; Padma Sheila Rajagopal; Afaf Osman; Robert H Collins; Raymond H Kim; Steven D Gore; Peter Greenberg; Lucy A Godley; Zejuan Li; Daniela Del Gaudio; Hari Prasanna Subramanian; Soma Das; Tom Walsh; Suleyman Gulsuner; Jeremy P Segal; Aliya N Husain; Sandeep Gurbuxani; Mary-Claire King; Mary E Strek; Jane E Churpek Journal: Blood Adv Date: 2020-10-13
Authors: Timothy S Blackwell; Justin C Hewlett; Wendi R Mason; Susan Martin; James Del Greco; Guixiao Ding; Pingsheng Wu; Lisa H Lancaster; James E Loyd; Rosemarie B Dudenhofer; Margaret L Salisbury; Jonathan A Kropski Journal: Ann Am Thorac Soc Date: 2021-08
Authors: Claire C Cutting; Willis S Bowman; Nam Dao; Janelle Vu Pugashetti; Christine Kim Garcia; Justin M Oldham; Chad A Newton Journal: Chest Date: 2021-01-21 Impact factor: 9.410
Authors: Ayodeji Adegunsoye; Julie Morisset; Chad A Newton; Justin M Oldham; Eric Vittinghoff; Angela L Linderholm; Mary E Strek; Imre Noth; Christine Kim Garcia; Paul J Wolters; Brett Ley Journal: Eur Respir J Date: 2021-03-04 Impact factor: 16.671
Authors: Julia Graham; Iazsmin Bauer Ventura; Chad A Newton; Cathryn Lee; Noelle Boctor; Janelle Vu Pugashetti; Claire Cutting; Elena Joerns; Habrinder Sandhu; Jonathan H Chung; Christine Kim Garcia; Michael Kadoch; Imre Noth; Ayodeji Adegunsoye; Mary E Strek; Justin M Oldham Journal: Eur Respir J Date: 2020-07-16 Impact factor: 16.671